Distribution of Improvements in Psoriasis Area and Severity Index from the Phase 2 Trial of Risankizumab in Moderate-to-Severe Plaque Psoriasis

Main Article Content

Bruce Strober
Kim A Papp
Mary Flack
Yihua Gu
Elizabeth HZ Thompson
Wendell C Valdecantos

Keywords

psoriasis, risankizumab, biologic therapy

Abstract

Abstract Not Available

 

Disclosures: Study supported by AbbVie.